Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Context Therapeutics Inc.
13G/A
Amendment 5
CNTX · 21077P108
|
8.7% |
5/12/2026
Event 3/31/2026
|
|||
| Avidity Partners Management LP | 8.7% | ||||
| Avidity Partners Management (GP) LLC | 8.7% | ||||
| Avidity Capital Partners Fund (GP) LP | 8.7% | ||||
| Avidity Capital Partners (GP) LLC | 8.7% | ||||
| Avidity Private Master Fund I LP | 7.7% | ||||
| Michael Gregory | 8.7% | ||||
|
Immunic, Inc.
13G
IMUX · 4525EP101
|
9.9% |
4/17/2026
Event 2/17/2026
|
|||
| Avidity Partners Management LP | 9.9% | ||||
| Avidity Partners Management (GP) LLC | 9.9% | ||||
| Avidity Capital Partners Fund (GP) LP | 9.9% | ||||
| Avidity Capital Partners (GP) LLC | 9.9% | ||||
| Avidity Private Master Fund I LP | 9.9% | ||||
| Michael Gregory | 9.9% | ||||
|
Perspective Therapeutics, Inc.
13G
CATX · 46489V302
|
5.3% |
3/10/2026
Event 2/20/2026
|
|||
| Avidity Partners Management LP | 5.3% | ||||
| Avidity Partners Management (GP) LLC | 5.3% | ||||
| Avidity Capital Partners Fund (GP) LP | 5.3% | ||||
| Avidity Capital Partners (GP) LLC | 5.3% | ||||
| Avidity Private Master Fund I LP | 5.1% | ||||
| Michael Gregory | 5.3% | ||||
|
Scynexis, Inc.
13G/A
Amendment 8
SCYX · 811292200
|
9.9%
Checked 5% or less
|
2/17/2026
Event 12/31/2025
|
|||
| Avidity Partners Management LP | 9.9% | ||||
| Avidity Partners Management (GP) LLC | 9.9% | ||||
| Avidity Capital Partners Fund (GP) LP | 9.9% | ||||
| Avidity Capital Partners (GP) LLC | 9.9% | ||||
| Avidity Master Fund LP | 2.0% | ||||
| Avidity Private Master Fund I LP | 8.1% | ||||
| Michael Gregory | 9.9% | ||||
|
Dianthus Therapeutics, Inc.
13D/A
Amendment 3
DNTH · 252828108
|
4.9% |
11/19/2025
Event 11/17/2025
|
|||
| Avidity Partners Management LP | 4.9% | ||||
| Avidity Partners Management (GP) LLC | 4.9% | ||||
| Avidity Capital Partners Fund (GP) LP | 4.9% | ||||
| Avidity Capital Partners (GP) LLC | 4.9% | ||||
| Avidity Private Master Fund I LP | 4.4% | ||||
| Michael Gregory | 4.9% | ||||
|
Context Therapeutics Inc.
13G/A
Amendment 4
CNTX · 21077P108
|
9.9%
Checked 5% or less
|
11/14/2025
Event 9/30/2025
|
|||
| Avidity Partners Management LP | 9.9% | ||||
| Avidity Partners Management (GP) LLC | 9.9% | ||||
| Avidity Capital Partners Fund (GP) LP | 9.9% | ||||
| Avidity Capital Partners (GP) LLC | 9.9% | ||||
| Avidity Master Fund LP | 4.9% | ||||
| Avidity Private Master Fund I LP | 8.2% | ||||
| Avidity Private Master Fund I LP | 8.2% | ||||
| Michael Gregory | 9.9% | ||||
|
Scynexis, Inc.
13G/A
Amendment 7
SCYX · 811292200
|
9.9% |
11/14/2025
Event 9/30/2025
|
|||
| Avidity Partners Management LP | 9.9% | ||||
| Avidity Partners Management (GP) LLC | 9.9% | ||||
| Avidity Capital Partners Fund (GP) LP | 9.9% | ||||
| Avidity Capital Partners (GP) LLC | 9.9% | ||||
| Avidity Master Fund LP | 8.5% | ||||
| Avidity Private Master Fund I LP | 9.9% | ||||
| Michael Gregory | 9.9% | ||||
|
Immunic, Inc.
13G/A
Amendment 5
IMUX · 4525EP101
|
4.8% |
11/14/2025
Event 9/30/2025
|
|||
| Avidity Partners Management LP | 4.8% | ||||
| Avidity Partners Management (GP) LLC | 4.8% | ||||
| Avidity Capital Partners Fund (GP) LP | 4.8% | ||||
| Avidity Capital Partners (GP) LLC | 4.8% | ||||
| Michael Gregory | 4.8% | ||||
|
Kezar Life Sciences, Inc.
13G/A
Amendment 4
KZR · 49372L209
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| Avidity Partners Management LP | 0% | ||||
| Avidity Partners Management (GP) LLC | 0% | ||||
| Avidity Capital Partners Fund (GP) LP | 0% | ||||
| Avidity Capital Partners (GP) LLC | 0% | ||||
| Avidity Master Fund LP | 0% | ||||
| Michael Gregory | 0% | ||||
|
Immunic, Inc.
13G/A
Amendment 4
IMUX · 4525EP101
|
5.9%
Checked 5% or less
|
8/14/2025
Event 6/30/2025
|
|||
| Avidity Partners Management LP | 5.9% | ||||
| Avidity Partners Management (GP) LLC | 5.9% | ||||
| Avidity Capital Partners Fund (GP) LP | 5.9% | ||||
| Avidity Capital Partners (GP) LLC | 5.9% | ||||
| Avidity Private Master Fund I LP | 4.9% | ||||
| Michael Gregory | 5.9% | ||||
|
Context Therapeutics Inc.
13G/A
Amendment 3
CNTX · 21077P108
|
9.9% |
8/14/2025
Event 6/30/2025
|
|||
| Avidity Partners Management LP | 9.9% | ||||
| Avidity Partners Management (GP) LLC | 9.9% | ||||
| Avidity Capital Partners Fund (GP) LP | 9.9% | ||||
| Avidity Capital Partners (GP) LLC | 9.9% | ||||
| Avidity Master Fund LP | 5.6% | ||||
| Avidity Private Master Fund I LP | 8.4% | ||||
| Michael Gregory | 9.9% | ||||
|
Immunic, Inc.
13G/A
Amendment 3
IMUX · 4525EP101
|
6.6% |
5/15/2025
Event 3/31/2025
|
|||
| Avidity Partners Management LP | 6.6% | ||||
| Avidity Partners Management (GP) LLC | 6.6% | ||||
| Avidity Capital Partners Fund (GP) LP | 6.6% | ||||
| Avidity Capital Partners (GP) LLC | 6.6% | ||||
| Avidity Private Master Fund I LP | 5.2% | ||||
| Michael Gregory | 6.6% | ||||
|
Dianthus Therapeutics, Inc. /DE/
13D/A
Amendment 2
DNTH · 252828108
|
9.9% |
3/19/2025
Event 3/17/2025
|
|||
| Avidity Partners Management LP | 9.9% | ||||
| Avidity Partners Management (GP) LLC | 9.9% | ||||
| Avidity Capital Partners Fund (GP) LP | 9.9% | ||||
| Avidity Capital Partners (GP) LLC | 9.9% | ||||
| Avidity Master Fund LP | 2.3% | ||||
| Avidity Private Master Fund I LP | 8.3% | ||||
| Michael Gregory | 9.9% | ||||
|
Kezar Life Sciences, Inc.
13G/A
Amendment 3
KZR · 49372L100
|
6.9%
Checked 5% or less
|
2/14/2025
Event 12/31/2024
|
|||
| Avidity Partners Management LP | 6.9% | ||||
| Avidity Partners Management (GP) LLC | 6.9% | ||||
| Avidity Capital Partners Fund (GP) LP | 6.9% | ||||
| Avidity Capital Partners (GP) LLC | 6.9% | ||||
| Avidity Master Fund LP | 6.9% | ||||
| David Witzke | 0% | ||||
| Michael Gregory | 6.9% | ||||
|
Perspective Therapeutics, Inc.
13G/A
Amendment 1
CATX · 46489V302
|
4.2% |
2/14/2025
Event 12/31/2024
|
|||
| Avidity Partners Management LP | 4.2% | ||||
| Avidity Partners Management (GP) LLC | 4.2% | ||||
| Avidity Capital Partners Fund (GP) LP | 4.2% | ||||
| Avidity Capital Partners (GP) LLC | 4.2% | ||||
| David Witzke | 0% | ||||
| Michael Gregory | 4.2% | ||||
|
Scynexis Inc
13G/A
Amendment 6
SCYX · 811292200
|
9.9%
Checked 5% or less
|
2/14/2025
Event 12/31/2024
|
|||
| Avidity Partners Management LP | 9.9% | ||||
| Avidity Partners Management (GP) LLC | 9.9% | ||||
| Avidity Capital Partners Fund (GP) LP | 9.9% | ||||
| Avidity Capital Partners (GP) LLC | 9.9% | ||||
| Avidity Master Fund LP | 9.9% | ||||
| Avidity Private Master Fund I LP | 9.9% | ||||
| David Witzke | 0% | ||||
| Michael Gregory | 9.9% | ||||
|
Immunic, Inc.
13G/A
Amendment 2
IMUX · 4525EP101
|
9.9%
Checked 5% or less
|
2/14/2025
Event 12/31/2024
|
|||
| Avidity Partners Management LP | 9.9% | ||||
| Avidity Partners Management (GP) LLC | 9.9% | ||||
| Avidity Capital Partners Fund (GP) LP | 9.9% | ||||
| Avidity Capital Partners (GP) LLC | 9.9% | ||||
| Avidity Private Master Fund I LP | 6.2% | ||||
| David Witzke | 0% | ||||
| Michael Gregory | 9.9% | ||||
|
Syros Pharmaceuticals, Inc.
13G/A
Amendment 4
SYRS · 87184Q206
|
7.6%
Checked 5% or less
|
2/14/2025
Event 12/31/2024
|
|||
| Avidity Partners Management LP | 7.6% | ||||
| Avidity Partners Management (GP) LLC | 7.6% | ||||
| Avidity Capital Partners Fund (GP) LP | 7.6% | ||||
| Avidity Capital Partners (GP) LLC | 7.6% | ||||
| Avidity Master Fund LP | 2.9% | ||||
| Avidity Private Master Fund I LP | 4.4% | ||||
| David Witzke | 0% | ||||
| Michael Gregory | 7.6% | ||||
|
Context Therapeutics Inc.
13G/A
Amendment 2
CNTX · 21077P108
|
9.9%
Checked 5% or less
|
2/14/2025
Event 12/31/2024
|
|||
| Avidity Partners Management LP | 9.9% | ||||
| Avidity Partners Management (GP) LLC | 9.9% | ||||
| Avidity Capital Partners Fund (GP) LP | 9.9% | ||||
| Avidity Capital Partners (GP) LLC | 9.9% | ||||
| Avidity Master Fund LP | 6.7% | ||||
| Avidity Private Master Fund I LP | 9.9% | ||||
| David Witzke | 0% | ||||
| Michael Gregory | 9.9% | ||||